Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Gemcitabine and Bevacizumab as First-Line Treatment in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer Previously Treated With Taxanes

NCT00623233 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00623233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00623233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Gemcitabine and Bevacizumab as First-Line Treatment in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer Previously Treated With Taxanes
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
January 31, 2011
Enrollment
52 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced breast cancer, metastatic breast cancer